Shuttle Pharmaceuticals Holdings, Inc. Common Stock
SHPH
SHPH: Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.
moreShow SHPH Financials
Recent trades of SHPH by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SHPH's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation May. 23, 2023
-
Patent Title: Selective histone deacetylase inhibitors for the treatment of human disease Feb. 21, 2023
-
Patent Title: Selective histone deacetylase inhibitors for the treatment of human disease Aug. 09, 2022
-
Patent Title: Selective histone deacetylase inhibitors for the treatment of human disease Jun. 15, 2021
-
Patent Title: Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof Aug. 18, 2020
-
Patent Title: Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof Aug. 04, 2020
-
Patent Title: Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof Nov. 07, 2017
Federal grants, loans, and purchases
Followers on SHPH's company Twitter account
Number of mentions of SHPH in WallStreetBets Daily Discussion
Recent insights relating to SHPH
Recent picks made for SHPH stock on CNBC
ETFs with the largest estimated holdings in SHPH
Flights by private jets registered to SHPH